Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Łukasiewicz, known for advanced chemical synthesis and production scaling capabilities, will help ExploRNA ramp up its mRNA manufacturing.
September 22, 2026
By: Patrick Lavery
Editor’s Take: Demand for high-quality, scalable components is growing rapidly as mRNA technology continues to change the biopharma landscape.
ExploRNA Therapeutics and the Łukasiewicz Research Network—Industrial Chemistry Institute (Łukasiewicz—IChP) announced a new strategic partnership. The collaboration involves delivering ExploRNA’s proprietary cap analogs, including the company’s AvantCap Q1 technology, in good manufacturing practice (GMP) quality.
As a biotechnology company specializing in novel messenger RNA (mRNA) capping technologies, ExploRNA says this secures essential raw material supply. From this partnership, ExploRNA anticipates producing clinical-stage mRNA therapeutics and vaccines.
This is crucial because as mRNA technology continues to impact the biopharmaceutical landscape, demand for high-quality, scalable component is growing.
According to ExploRNA, co-transcriptional capping is critical to mRNA manufacturing. It directly affects yield, quality, and translation efficiency of the final drug product. In this way, Łukasiewicz—IChP will help as it is known for advanced chemical synthesis and production scaling capabilities.
“This collaboration with Łukasiewicz—IChP marks a critical milestone in our growth trajectory,” ExploRNA CEO Jacek Jemielity said. “Securing a reliable, high-quality GMP manufacturing partner is an important development step for ExploRNA.”
Jemielity adds the partnership validates the scalability of ExploRNA’s synthesis processes, while ensuring proprietary innovations transition from lab to clinic.
Ultimately, ExploRNA wants to provide industry partners with premium-grade cap analog access, necessary to advance clinical programs and commercial pipelines. For the advancement of the company’s own commercial strategy, then, it says production of GMP-grade materials is critical.
In short, ExploRNA hopes to support biotech and pharma developers from early-stage research, to late-stage clinical trials, then full-scale commercialization.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
